Imatinib resistance was reversed by nilotinib in the acute transformation of chronic myeloid leukemia: A case report | Zendy

Xiao Meng | Zendy; Zhou Hongjing | Zendy; Li Shuguo | Zendy; Xin Chunlei | Zendy; Zhao Tongfeng | Zendy; Hao Yunliang | Zendy; Li Shumei | Zendy; Liang Yanyan | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Imatinib resistance was reversed by nilotinib in the acute transformation of chronic myeloid leukemia: A case report

Author(s) -

Xiao Meng,

Zhou Hongjing,

Li Shuguo,

Xin Chunlei,

Zhao Tongfeng,

Hao Yunliang,

Li Shumei,

Liang Yanyan

Publication year - 2017

Publication title -

precision radiation oncology

Language(s) - English

Resource type - Journals

ISSN - 2398-7324

DOI - 10.1002/pro6.31

Subject(s) - nilotinib , imatinib , myeloid leukemia , cancer research , tyrosine kinase inhibitor , philadelphia chromosome , tyrosine kinase , medicine , fusion gene , dasatinib , oncology , immunology , biology , chromosomal translocation , genetics , gene , cancer , receptor

Chronic myeloid leukemia (CML) is a clonal malignant hematopoietic disorder that arises in a hematopoietic stem cell. Its characteristic cytogenetic abnormality is an abnormal chromosome 22 called the Philadelphia (Ph) chromosome. The BCR ‐ ABL1 fusion gene in this chromosome can encode a tyrosine protein kinase and is the molecular basis of CML pathogenesis. The tyrosine kinase inhibitor (TKI) imatinib is the ‘gold standard’ therapy for the treatment of CML. However, around 30% of the patients develop imatinib resistance. In this report, we will illustrate a case of an adult female with acute transformation of CML whose imatinib resistance was reversed by nilotinib and has had a long‐term survival.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research